• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

CN Bio appoints Dr Paul Brooks as Chief Business Officer

May 24, 2022

Cambridge, UK, 24 May 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks as Chief Business Officer. Key to the next stage of the Company’s growth, Paul will be responsible for shaping the company’s commercial business strategy and leading the expansion of its global commercial organisation.

Paul Brooks |Paul is an experienced C-suite level executive with over 25 years in the life science industry building businesses and leading high-performance research, product development, marketing, and sales teams to develop and commercialise new biotechnology technologies. He joins CN Bio from Horizon Discovery, a PerkinElmer Company, where he led the strategic and operational transformation of its business units as Head of Business Operations & Managing Director, driving revenue growth across its service, product, and licensing businesses. Paul held various management roles at Sigma-Aldrich; acquired by Merck Group in 2015 to form MilliporeSigma, where he joined the leadership team as Head of Discovery Research Services & General Manager and led the successful formation of its global-leading product and service portfolio for drug discovery research. In 2016, he relocated back to the UK as Chief Commercial Officer & Executive Director and Board member at Oxford Genetics, driving the rapid scaling of the synthetic biology start-up company and commercialisation of its technology.

Paul has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology, and an MBA from University of Nottingham Business School.


Dr David Hughes, Chief Executive Officer, CN Bio, said: “Paul not only has experience across a range of large, globally-recognised life sciences businesses, but also driving growth within smaller teams. He has a very strong track record and is well placed to help us grow commercially, moving us forward with our organisational strategy and goals. We are proud to have him joining the team and look forward to working together, enabling us to drive innovation in the sector by bringing more products to market.”


Dr Paul Brooks, Chief Business Officer, CN Bio, commented: “The potential within the Organ-on-a-Chip space to revolutionise drug discovery is remarkable. CN Bio is demonstrating these possibilities with its next-generation PhysioMimix microphysiological technology, not only to accelerate the accurate and reliable development of new therapeutics, but also critically reducing researchers’ dependence on animal models. It’s an exciting time to be joining CN Bio at an important inflection point in its history, and I’m eager to work alongside the team to help realise this potential.”

For more information on the PhysioMimix OOC range please visit: https://cn-bio.com/physiomimixooc

Category iconPress releases

Primary Sidebar

Other recent news

  • CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development June 10, 2025
  • CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea May 20, 2025
  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
  • Why the FDA animal testing phase-out for monoclonal antibodies? May 1, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research April 29, 2025

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development June 10, 2025
  • CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea May 20, 2025
  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
Cyber Essentials Logo